On September 10, 2026 Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, reported that a poster evaluating botensilimab (BOT), an Fc-enhanced multifunctional anti-CTLA-4 antibody, in combination with balstilimab (BAL), an anti-PD-1 antibody, has been accepted for presentation at the International Gynecologic Cancer Society (IGCS) Annual Global Meeting, taking place October 1–3, 2026, in Montreal, Canada.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation will feature results from the recurrent ovarian cancer cohort of the large Phase 1b C-800-01 study, including patients with platinum-refractory/resistant disease, with analyses by platinum sensitivity status and long-term three-year overall survival.

Presentation Details:

Abstract Title: Next Generation Immune Checkpoint Inhibition with Botensilimab Plus Balstilimab in Recurrent Ovarian Cancer: Results by Platinum Sensitivity Status and 3-Year Overall Survival
Presenter: Rebecca L. Porter, M.D.; Dana-Farber Cancer Institute, Boston, MA, USA
Poster Presentation number: 969
Session Title: Poster Rounds with Professors Session, Ovarian Cancer 03 Session
Date/Time: Saturday, October 3, 2026 | 10:50am-10:55am EDT

(Press release, Agenus, SEP 10, 2026, View Source [SID1234670727])